FDA Approves Merck’s RECARBRIO™ for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

  06 June 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacaeEscherichia coliHaemophilus influenzaeKlebsiella aerogenesKlebsiella oxytocaKlebsiella pneumoniaePseudomonas aeruginosa and Serratia marcescens

Further reading: Business Wire
Author(s): Business Wire
Healthy Animals   Smart Innovations  
Back


Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market
  • Global reach for funding / co-development / licensing
Display your technology and make use of the Continuous AMR Partnering Initiative >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!